Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage

  Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and
  Announces Multiple, Diverse, Early-Stage Collaborations with Academia and

Business Wire

NEW BRUNSWICK, N.J. -- January 8, 2014

Johnson & Johnson Innovation today announced that it is expanding its global
incubator presence through a novel collaboration with the Office of the Chief
Scientist in Israel and other industry partners to establish a new
biotechnology incubator near Israel’s Weizmann Science Park. This is the
latest in a series of recently announced collaborations to fuel
entrepreneurship in the world’s scientific hotspots. In addition, Johnson &
Johnson Innovation announced several new collaborations with academia and
biotech that focus on multiple disease areas and consumer healthcare
challenges. These customized collaborations are part of Johnson & Johnson
Innovation’s strategy to support an international network of scientific
entrepreneurs through access to best-in-class laboratory facilities,
scientific expertise, and funding.

The new research and development collaborations span Europe and the United
States and include the University of Texas MD Anderson Cancer Center, and
seven biotechnology companies: California-based Assembly Pharmaceuticals,
Nodality and SutroVax; London-based TopiVert; Maryland-based Intrexon;
Massachusetts-based Scholar Rock; and Netherlands-based Bioceros.

“Addressing today’s unmet medical needs requires accessing the best science in
the world and the best minds in the world working on it,” said Paul Stoffels,
Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson &
Johnson. “Johnson & Johnson Innovation is proud to be working with many
partners to accelerate the pace of innovation on behalf of patients and
consumers, and to unleash the creativity and entrepreneurship of scientists to
solve today’s healthcare problems.”

Expanding Global Incubator Presence to Israel

An outcome of a novel collaboration among Johnson & Johnson Innovation and
Johnson & Johnson Development Corporation (JJDC), the Office of the Chief
Scientist in Israel, Takeda Pharmaceutical Company, and OrbiMed Israel
Partners, is a public-private biotechnology incubator that will be located
near the Weizmann Science Park, Rehovot, Israel. The Weizmann Science Park
area is considered to be one of the foremost centers in the world for
multidisciplinary research, and is the location of a Johnson & Johnson
Innovation satellite office.

“A key aim of Johnson & Johnson Innovation is to find novel ways of advancing
the most promising early-stage science,” said Patrick Verheyen, Head of
Johnson & Johnson Innovation, London. “The formation of the new biotechnology
incubator in Israel is the product of an important collaboration between
government, industry, and venture capital that demonstrates a multi-partner
approach in practice. The collaboration provides a unique platform to support
and advance new companies with not only funding, but also strategic advice
from both venture capital and industry pharmaceutical development experts.”

The new incubator, which will be operational in early 2014, is the latest in a
series of recently announced collaborations with other biotechnology
incubators to fuel entrepreneurship, including Montreal-based NEOMED;
Toronto-based MaRS Innovation; San Francisco-based California Institute for
Quantitative Biosciences (QB3); and Boston-based LabCentral. These
announcements build upon the growing success of Janssen Labs, the 40,000
square foot flagship facility that opened in early 2012 in San Diego at
Janssen’s West Coast Research Center.

New and Customized Early Stage Collaborations

The eight new early stage collaborations announced today represent recent
deals closed by the Boston, California, and London innovation centers that are
forging important research and development alliances across Johnson &
Johnson’s three business areas: Consumer; Medical Devices & Diagnostics; and

“Through our customized deals and incubator strategy, we are collaborating
with the world’s best innovators and academia to discover and develop the next
generation of breakthrough medical solutions,” said Diego Miralles, Head of
Johnson & Johnson Innovation, California and Global Head Innovation, Janssen

Johnson & Johnson Innovation officially opened its innovation centers a little
more than a year ago, establishing four regional hubs to identify scientific
opportunities with the potential to advance the development of new healthcare

Today, there are three fully operational offices in Boston, London, and
California, and a fourth location in Shanghai now houses a few scientific
experts and will officially open this year.

“An exciting and common factor for many of the collaborations we announced
today is how we are working together to leverage our collective and deep
knowledge about specific biologic pathways and disease areas,” said Robert
Urban, Head of Johnson & Johnson Innovation, Boston. “This approach offers the
potential to make strong research decisions that can ultimately support
company and program success.”

New collaborations include:

Boston Innovation Center

  *Translational Oncology Research Alliance with the University of Texas MD
    Anderson Cancer Center – Janssen Biotech, Inc. and Johnson & Johnson
    Innovation have established a translational oncology program with the
    University of Texas MD Anderson Cancer Center to enable the
    personalization of immunotherapies for the treatment of various cancers.
    Researchers and clinicians will work in partnership to leverage shared
    scientific and clinical capabilities to decipher the immuno-oncology code,
    with the intent to enable durable clinical response, rational combination
    strategies, precision medicine approaches, and identification of new
    opportunities for therapeutic interventions.
  *Skin and Hair Care Research & Development Collaboration with Intrexon
    Corporation – Johnson & Johnson Consumer & Personal Products Worldwide and
    Johnson & Johnson Innovation have established a research and development
    collaboration with synthetic biology company Intrexon Corporation to
    advance new skin and hair care products. Through the collaboration,
    technical experts at both companies will work together to explore, define,
    and test new potential products for consumers.
  *Novel Biologics Collaboration with Scholar Rock, Inc. – Janssen Biotech,
    Inc. and Johnson & Johnson Innovation have formed a collaboration with the
    biotechnology company Scholar Rock, Inc. to discover and develop novel
    biologics, called niche activators, to target TGF-beta 1 in the immune
    system microenvironment and offer a potential new therapeutic approach for
    autoimmune diseases and cancer immunotherapies. Immunologists from the
    Johnson & Johnson Innovation Center in Boston and Janssen Biotech will
    work with Scholar Rock to therapeutically target the TGF-beta 1 activation
    mechanism by applying Scholar Rock’s proprietary technology platform.

California Innovation Center

  *Virology-Focused Investment in Assembly Pharmaceuticals – JJDC, in
    collaboration with Johnson & Johnson Innovation, has made an investment in
    Assembly Pharmaceuticals, a virology-focused biotech company with a
    discovery platform based on proprietary Core Protein Allosteric Modulators
    (CpAMs) for the treatment of viral infections, starting with Hepatitis B
    (HBV). CpAMs are being studied for their potential to become curative
    rather than suppressive therapies. Assembly is located at Janssen Labs
    @QB3 in San Francisco, Calif.
  *Single Cell Network Profiling Collaboration with Nodality, Inc. – Janssen
    Biotech, Inc. and Johnson & Johnson Innovation have formed a collaboration
    with the biotechnology company Nodality, Inc. to apply Nodality’s
    proprietary Single Cell Network Profiling (SCNP) technology to immunology
    R&D programs. The goal of the collaboration is to improve the development
    and probability of success of compounds for the treatment of rheumatoid
    arthritis and inflammatory bowel disease by further understanding the
    biologic function and activity at the single cell level.
  *Vaccine New Company Creation Investment in SutroVax – Johnson & Johnson
    Innovation, through the JJDC, and Sutro Biopharma, a privately funded
    company, have co-funded a new company, SutroVax. SutroVax will leverage
    Sutro Biopharma’s Xpress CF™ cell-free biochemical protein synthesis
    platform to develop novel vaccines for a broad range of disease targets.

London Innovation Center

  *Monoclonal Antibody Licensing agreement with Bioceros – Janssen
    Pharmaceuticals Inc. and Johnson & Johnson Innovation have announced an
    agreement with Dutch biotechnology company Bioceros under which Bioceros,
    through its affiliated company BiocerOX Products B.V., has granted Janssen
    exclusive worldwide rights to develop a monoclonal antibody directed at an
    immune checkpoint modulator. The agreement reflects the growing interest
    in modulating a patient’s immune responses as a therapeutic approach with
    the potential to target a variety of tumors at all stages of disease.
  *Topical Medicines Investment in TopiVert – JJDC, in collaboration with
    Johnson & Johnson Innovation has made an investment in TopiVert, a company
    focused on developing topical medicines for inflammatory diseases of the
    gut and eye based on NSKI (narrow spectrum kinase inhibitor) technology.
    JJDC and NeoMed Management join existing investors SV Life Sciences and
    Imperial Innovations Group PLC in this round of funding.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation, LLC focuses on accelerating early-stage
innovation worldwide and forming collaborations between entrepreneurs and
Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation
provides scientists, entrepreneurs and emerging companies one-stop access to
science and technology experts who can facilitate collaborations across the
pharmaceutical, medical device and diagnostics and consumer companies of
Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making
capabilities with the flexibility to adapt deal structures to match
early-stage opportunities and establish novel collaborations that speed
development of innovations to solve unmet needs in patients. For more
information please visit:

About Johnson & Johnson Development Corporation

Johnson & Johnson Development Corporation (JJDC) is the venture capital
subsidiary of Johnson & Johnson, with investment activity in the medical
device, diagnostic, pharmaceutical, and consumer health areas. Our goal is to
create opportunities that meet the strategic needs of our operating affiliates
while providing visibility to innovative emerging technology, businesses and
business models. JJDC measures the success of an investment’s performance not
only in financial returns, but also in the viability of providing strategic
growth opportunities for the Johnson & Johnson Family of Companies. JJDC is
interested in opportunities that address significant unmet medical needs, have
clear competitive advantages, IP protection, an executable clinical and
commercialization plan, and are led by experienced management. JJDC invests in
companies across the continuum from early stage seed investments to the
advanced stages of series venture management. Our investment teams are based
predominantly in Johnson & Johnson Innovation’s four regional centers in
Boston, California, London, and Shanghai. For more information, please visit:

About Janssen Biotech, Inc. and Janssen Pharmaceuticals, Inc.

At Janssen, we are dedicated to addressing and solving some of the most
important unmet medical needs of our time in oncology, immunology,
neuroscience, infectious diseases and vaccines, and cardiovascular and
metabolic diseases. Driven by our commitment to patients, we develop
innovative products, services and healthcare solutions to help people with
serious diseases throughout the world. Beyond its innovative medicines,
Janssen is at the forefront of developing education and public policy
initiatives to ensure patients and their families, caregivers, advocates and
healthcare professionals have access to the latest treatment information,
support services and quality care.

Janssen Biotech, Inc.  and Janssen Pharmaceuticals, Inc.  are two of the
Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit for more information.


Global Enterprise Innovation
Seema Kumar, 908-405-1144
Boston Innovation Center
John Lacey, 781-392-5514
California Innovation Center
Meghan Marschall, 201-323-0578
London Innovation Center
Ellen Rose, +44 (0) 7767 267493
Press spacebar to pause and continue. Press esc to stop.